Company Reports First Cellvizio System Sales in Japan, World's Second Largest Healthcare Market
•At the beginning of 2013, physicians at Japanese medical schools, including the Hirosaki University Graduate School of Medicine in Aomori, have acquired two Cellvizio systems to better understand stomach, pancreatic and esophageal cancers, as well as common functional gastrointestinal and motility disorders such as irritable bowel syndrome (IBS), gastro esophageal reflux disease (GERD) and chronic constipation.
Revolutionary Cellvizio Dual Band Color Lab Imaging System Launched
•Cellvizio Dual Band, launched September 2012, incorporates color into the state-of-the-art molecular imaging system that allows researchers to visualize both structural and functional information of tissue inside animals' bodies in real time.
Next Quarterly Financial Press Release: 2013 First Quarter Sales, April 16, 2013 (post-market)
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers ("AMF") granted its visa number 11-236 on June 20, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Tel: +1 917 497 2867
France and Europe
Investor Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel: +33(0)1 44 71 94 94
Mauna Kea Technologies
Vice President, Finance
Tel: + 33 1 70 08 09 86
Most Popular Stories
- 2014 Will Be 'Breakthrough Year' for U.S., Obama Says
- Climate Change Isn't an Equal Opportunity Destroyer
- Renewable Energy Group to Acquire Syntroleum
- Ally Financial Settles Auto Loan Suit
- Kanye, Kardashians and Other Kooks: A Wacky, Tacky, Entertaining Year
- Covered California Lags on Hispanic Enrollment
- Luis Suarez Re-ups With Liverpool F.C.
- Chris Christie Set to Sign Tuition Aid Bill
- Little Risk of Deportation Under Obama
- Time No Longer Stands Still for Cuban Entrepreneurs